Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress

American Journal of Physiology - Cell Physiology

Volumn 295, Issue 4, 2008, Pages

  Speich, Henry E ^a,b   Grgurevich, Svetozar ^b   Kueter, Teddi J ^b   Earhart, Angela D ^b   Slack, Steven M ^a   Jennings, Lisa K ^a,b,c  

^a University of Memphis ^*  (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Collagen; GPIb; GPIIb IIIa; Signal transduction; Thrombosis

Indexed keywords

3 (1 METHYL 1H INDOL 3 YL METHYLENE) 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONAMIDE; ADENOSINE DIPHOSPHATE; ANTIBODY; COLLAGEN TYPE 3; FIBRINOGEN RECEPTOR; PICEATANNOL; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; PROTEIN TYROSINE KINASE; SULFONAMIDE; THROMBOXANE A2; TYROSINE; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SHEAR STRESS; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

BLOOD PLATELETS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; SHEAR STRENGTH;

ANGINA;

EID: 54049118714     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.90644.2007     Document Type: Article

References (77)

1. Andre P, Arbeille B, Drouet V, Hainaud P, Bal dit Sollier C, Caen JP, Drouet LO. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion chamber study in the guinea pig. Arterioscler Thromb Vasc Biol 16: 56-63, 1996.
2. Arderiu G, Diaz-Ricart M, Buckley B, Escolar G, Ordinas A. Primary arrest of circulating platelets on collagen involves phosphorylation of Syk, cortactin and focal adhesion kinase: studies under flow conditions. Biochem J 364: 65-71, 2002.
3. Asazuma N, Ozaki Y, Satoh K, Yatomi Y, Handa M, Fujimura Y, Miura S, Kume S. Glycoprotein Ib-von Willebrand factor interactions activate tyrosine kinases in human platelets. Blood 90: 4789-4798, 1997.
4. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 371: 199-204, 2003.
5. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315, 2007.
6. Bhavaraju K, Kim S, Daniel JL, Kunapuli SP. Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5- sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets. Eur J Pharmacol 2007.
7. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, Courtneidge SA. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20: 9018-9027, 2000.
8. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319: 998-1008, 2006.
9. Brunati AM, Deana R, Folda A, Massimino ML, Marin O, Ledro S, Pinna LA, Donella-Deana A. Thrombin-induced tyrosine phosphorylation of HS1 in human platelets is sequentially catalyzed by Syk and Lyn tyrosine kinases and associated with the cellular migration of the protein. J Biol Chem 280: 21029-21035, 2005.
10. Canobbio I, Bertoni A, Lova P, Paganini S, Hirsch E, Sinigaglia F, Balduini C, Torti M. Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and Fc gamma IIA receptor. J Biol Chem 276: 26022-26029, 2001.
11. Canobbio I, Lova P, Sinigaglia F, Balduini C, Torti M. Proline-rich tyrosine kinase 2 and focal adhesion kinase are involved in different phases of platelet activation by vWF. Thromb Haemost 87: 509-517, 2002.
12. Cauwenberghs N, Ajzenberg N, Vauterin S, Hoylaerts MF, Declerck PJ, Baruch D, Deckmyn H. Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin-induced glycoprotein Ib-von Willebrand factor interaction. Haemostasis 30: 139-148, 2000.
13. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 61: 99-110, 1983.
14. Feng S, Lu X, Resendiz JC, Kroll MH. Pathological shear stress directly regulates platelet αIIbβ3 signaling. Am J Physiol Cell Physiol 291: C1346-C1354, 2006.
15. Fujii C, Yanagi S, Sada K, Nagai K, Taniguchi T, Yamamura H. Involvement of protein-tyrosine kinase p72syk in collagen-induced signal transduction in platelets. Eur J Biochem 226: 243-248, 1994.
16. Gao J, Zoller KE, Ginsberg MH, Brugge JS, Shattil SJ. Regulation of the pp72syk protein tyrosine kinase by platelet integrin α IIbβ3. EMBO J 16: 6414-6425, 1997.
17. Glantz SA. A Primer of Biostatistics. New York: McGraw-Hill, 1997.
18. Goto S, Sakai H, Goto M, Ono M, Ikeda Y, Handa S, Ruggeri ZM. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 99: 608-613, 1999.
19. Groesch TD, Zhou F, Mattila S, Geahlen RL, Post CB. Structural basis for the requirement of two phosphotyrosine residues in signaling mediated by Syk tyrosine kinase. J Mol Biol 356: 1222-1236, 2006.
20. Haga JH, Jennings LK, Slack SM. Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists. Ann Biomed Eng 30: 1262-1272, 2002.
21. Haga JH, Slack SM, Jennings LK. Comparison of shear stress-induced platelet microparticle formation and phosphatidylserine expression in presence of alphaIIbbeta3 antagonists. J Cardiovasc Pharmacol 41: 363-371, 2003.
22. Hainaud P, Brouland JP, Andre P, Simoneau G, Bal Dit Sollier C, Drouet L, Caen J, Bellucci S. Dissociation between fibrinogen and fibrin interaction with platelets in patients with different subtypes of Glanzmann's thrombasthenia: studies in an ex vivo perfusion chamber model. Br J Haematol 119: 998-1004, 2002.
23. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271: 695-701, 1996.
24. Hoylaerts MF, Viaene A, Thys C, Deckmyn H, Vermylen J. Anti-vWf antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear forces. J Thromb Thrombolysis 12: 249-262, 2001.
25. Konstantopoulos K, Grotta JC, Sills C, Wu KK, Hellums JD. Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost 74: 1329-1334, 1995.
26. Kroll MH, Feng S. Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal? Expert Rev Cardiovasc Ther 3: 941-951, 2005.
27. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 88: 1525-1541, 1996.
28. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest 105: 783-791, 2000.
29. Lai JY, Cox PJ, Patel R, Sadiq S, Aldous DJ, Thurairatnam S, Smith K, Wheeler D, Jagpal S, Parveen S, Fenton G, Harrison TK, McCarthy C, Bamborough P. Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorg Med Chem 13: 3111-3114, 2003.
30. Law CL, Chandran KA, Sidorenko SP, Clark EA. Phospholipase C-gamma1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. Mol Cell Biol 16: 1305-1315, 1996.
31. Law DA, Nannizzi-Alaimo L, Ministri K, Hughes PE, Forsyth J, Turner M, Shattil SJ, Ginsberg MH, Tybulewicz VL, Phillips DR. Genetic and pharmacological analyses of Syk function in alphaIIbbeta3 signaling in platelets. Blood 93: 2645-2652, 1999.
32. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 108: 2596-2603, 2006.
33. Liu J, Pestina TI, Berndt MC, Jackson CW, Gartner TK. Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alphaIIbbeta3- and aggregation-independent manner. Blood 106: 2750-2756, 2005.
34. Maalej N, Folts JD. Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Circulation 93: 1201-1205, 1996.
35. Marshall SJ, Asazuma N, Best D, Wonerow P, Salmon G, Andrews RK, Watson SP. Glycoprotein IIb-IIIa-dependent aggregation by glycoprotein Ibalpha is reinforced by a Src family kinase inhibitor (PP1)-sensitive signalling pathway. Biochem J 361: 297-305, 2002.
36. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 115: 791-796, 2005.
37. Michelson AD. (Editor). Platelets. New York: Academic, 2002.
38. Michelson AD, Loscalzo J, Melnick B, Coller BS, Handin RI. Partial characterization of a binding site for von Willebrand factor on glycocalicin. Blood 67: 19-26, 1986.
39. Minuz P, Fumagalli L, Gaino S, Tommasoli RM, Degan M, Cavallini C, Lecchi A, Cattaneo M, Lechi Santonastaso C, Berton G. Rapid stimulation of tyrosine phosphorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human platelets. Biochem J 400: 127-134, 2006.
40. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71: 1366-1374, 1988.
41. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 78: 1456-1461, 1986.
42. Moon KD, Post CB, Durden DL, Zhou Q, De P, Harrison ML, Geahlen RL. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem 280: 1543-1551, 2005.
43. Nashar TO, Drake JR. Dynamics of MHC class II-activating signals in murine resting B cells. J Immunol 176: 827-838, 2006.
44. Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, Lowell CA, Shattil SJ. Coordinate interactions of Csk, Src, and Syk kinases with αIIbβ3 initiate integrin signaling to the cytoskeleton. J Cell Biol 157: 265-275, 2002.
45. Ohmori T, Yatomi Y, Asazuma N, Satoh K, Ozaki Y. Involvement of proline-rich tyrosine kinase 2 in platelet activation: tyrosine phosphorylation mostly dependent on alphaIIbbeta3 integrin and protein kinase C, translocation to the cytoskeleton and association with Shc through Grb2. Biochem J 347: 561-569, 2000.
46. Oliver JM, Burg DL, Wilson BS, McLaughlin JL, Geahlen RL. Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem 269: 29697-29703, 1994.
47. Olynych TJ, Jakeman DL, Marshall JS. Fungal zymosan induces leukotriene production by human mast cells through a dectin-1-dependent mechanism. J Allergy Clin Immunol 118: 837-843, 2006.
48. Pilling D, Tucker NM, Gomer RH. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 79: 1242-1251, 2006.
49. Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T, Tybulewicz VL, Watson SP. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 16: 2333-2341, 1997.
50. Rao N, Ghosh AK, Ota S, Zhou P, Reddi AL, Hakezi K, Druker BK, Wu J, Band H. The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. EMBO J 20: 7085-7095, 2001.
51. Resendiz JC, Feng S, Ji G, Francis KA, Berndt MC, Kroll MH. Purinergic P2Y12 receptor blockade inhibits shear-induced platelet phosphatidylinositol 3-kinase activation. Mol Pharmacol 63: 639-645, 2003.
52. Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, Williams DL, Gordon S, Tybulewicz VL, Brown GD, Reis e Sousa C. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22: 507-517, 2005.
53. Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem (Tokyo) 130: 177-186, 2001.
54. Sarkar S, Rooney MM, Lord ST. Activation of integrin-beta3- associated syk in platelets. Biochem J 338: 677-680, 1999.
55. Shankar H, Garcia A, Prabhakar J, Kim S, Kunapuli SP. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 4: 638-647, 2006.
56. Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. Blood 101: 2637-2645, 2003.
57. Shrimpton CN, Borthakur G, Larrucea S, Cruz MA, Dong JF, Lopez JA. Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation. J Exp Med 196: 1057-1066, 2002.
58. Simon M, Vanes L, Geahlen RL, Tybulewicz VL. Distinct roles for the linker region tyrosines of Syk in FcepsilonRI signaling in primary mast cells. J Biol Chem 280: 4510-4517, 2005.
59. Slack SM, Jennings LK, Turitto VT. Platelet size distribution measurements as indicators of shear stress-induced platelet aggregation. Ann Biomed Eng 22: 653-659, 1994.
60. Slack SM, Turitto VT. Fluid dynamic and hemorheologic considerations. Cardiovasc Pathol 2: 11S-22S, 1993.
61. Slack SM, Turitto VT. Flow chambers and their standardization for use in studies of thrombosis. On behalf of the Subcommittee on Rheology of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 72: 777-781, 1994.
62. Sullam PM, Hyun WC, Szollosi J, Dong J, Foss WM, Lopez JA. Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor FcgammaRIIA on the platelet plasma membrane. J Biol Chem 273: 5331-5336, 1998.
63. Sun L, Feng S, Resendiz JC, Lu X, Durante W, Kroll MH. Role of the Pyk2-MAP kinase-cPLA2 signaling pathway in shear-dependent platelet aggregation. Ann Biomed Eng 32: 1193-1201, 2004.
64. Suzuki-Inoue K, Wilde JI, Andrews RK, Auger JM, Siraganian RP, Sekiya F, Rhee SG, Watson SP. Glycoproteins VI and Ib-IX-V stimulate tyrosine phosphorylation of tyrosine kinase Syk and phospholipase Cgamma2 at distinct sites. Biochem J 378: 1023-1029, 2004.
65. Taniguchi T, Kitagawa H, Yasue S, Yanagi S, Sakai K, Asahi M, Ohta S, Takeuchi F, Nakamura S, Yamamura H. Protein-tyrosine kinase p72syk is activated by thrombin and is negatively regulated through Ca2+ mobilization in platelets. J Biol Chem 268: 2277-2279, 1993.
66. Thomson CW, Teft WA, Chen W, Lee BP, Madrenas J, Zhang L. FcR gamma presence in TCR complex of double-negative T cells is critical for their regulatory function. J Immunol 177: 2250-2257, 2006.
67. Torti M, Bertoni A, Canobbio I, Sinigaglia F, Lapetina EG, Balduini C. Rap1B and Rap2B translocation to the cytoskeleton by von Willebrand factor involves FcgammaII receptor-mediated protein tyrosine phosphorylation. J Biol Chem 274: 13690-13697, 1999.
68. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 98: 3340-3345, 2001.
69. Ulanova M, Duta F, Puttagunta L, Schreiber AD, Befus AD. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin Ther Targets 9: 901-921, 2005.
70. Ulanova M, Puttagunta L, Kim MK, Schreiber AD, Befus AD. Antisense oligonucleotides to Syk kinase: a novel therapeutic approach for respiratory disorders. Curr Opin Investig Drugs 4: 552-555, 2003.
71. White MM, Jennings LK. Platelet Protocols. San Diego, CA: Academic, 1999.
72. Witting JI, Miller TM, Fenton JW, 2nd. Human alpha- and gamma-thrombin specificity with tripeptide p-nitroanalide substrates under physiologically relevant conditions. Thromb Res 46: 567-574, 1987.
73. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13: 743-762, 2004.
74. Woodside DG, Obergfell A, Leng L, Wilsbacher JL, Miranti CK, Brugge JS, Shattil SJ, Ginsberg MH. Activation of Syk protein tyrosine kinase through interaction with integrin beta cytoplasmic domains. Curr Biol 11: 1799-1804, 2001.
75. Yang Z, Mosser DM, Zhang X. Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages. J Immunol 178: 1077-1085, 2007.
76. Zhang J, Billingsley ML, Kincaid RL, Siraganian RP. Phosphorylation of Syk activation loop tyrosines is essential for Syk function. An in vivo study using a specific anti-Syk activation loop phosphotyrosine antibody. J Biol Chem 275: 35442-35447, 2000.
77. Zhang S, Phillips JH. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukoc Biol 79: 363-368, 2006.